I have been working at Clarion | A Life Sciences Consultancy full-time
Truly focused on most strategic and impactful projects in life science industry
Firm leadership involved in project work, providing learning opportunities for younger staff
Meritocratic promotion policies
Smart and friendly people make for collaborative culture
Flat structure can make promotions few and far between
Compensation lower than many competitors, especially when bonuses are lower due to firm profitability.
I applied through college or university. The process took 3 weeks. I interviewed at Clarion | A Life Sciences Consultancy (Boston, MA).
I applied through my school's job board.
A week later I had a 45 minute interview with an on campus recruiter. She was very sociable, friendly. She was very good at listening and asking relevant follow up questions to what I was saying - and I feel like she really cared about what I was saying.
The next round was 4 or so 30-45 minute (depending how far over they went) interviews. The interview I had with the partners were phenomenal. Very relatable, friendly, and easy to talk to. The interviews I had with other recent hires and managers were ok.
I came back up the following week for another half day of interviews with members of the recruiting team.
Reasons for Declining
It was a really hard decision for me. I really liked this place and another place that I was deciding between. Honestly it came down to firm culture, and I could see myself liking the other place more. I know that this place would have been a fantastic place to work!
Clarion continues its fall recruiting tour this week at the Dartmouth College Employer Connections Fair. We look forward to meeting students interested in a career in life sciences strategy consulting! For the full calendar of recruiting events that Clarion will be attending, see the link below.
We are excited to announce that In Vivo published an article written by Clarion’s medical director, Amama Sadiq MD, MPH et al. This thought piece discusses the key challenges and potential solutions associated with drug development and commercialization in non-alcoholic steatohepatitis (NASH). NASH is an emerging therapeutic area that is currently attracting substantial interest and investment from the biopharma space. A silent epidemic of the western world triggered by a surge in obesity and metabolic risk factors, NASH affects upwards of 10-15 million Americans and (along with its precursor form NAFLD) is estimated to cost the U.S. more than $100B annually. With no approved therapies for this deadly condition, the unmet medical need is exceptionally high.
To learn more about Clarion’s unique insights on NASH, please read the full article: http://glassdoor.com/slink.htm?key=vQm8M
Let us know if we're missing any workplace or industry recognition –